Investor mix
5 investors on record; lead investors include Forward Ventures, Ontario Capital Growth Corporation; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 5 | 100% |
Canadian, clinical stage biopharma developing bacterial FAS II-inhibitors, highly specific to Staphylococcus sp. Acquired by Debiopharm
5 investors on record; lead investors include Forward Ventures, Ontario Capital Growth Corporation; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 5 | 100% |